Document is current

Article History

Accepted: 17 December 2024

First Online: 19 January 2025

Declarations

:

: This study was sponsored by Janssen Scientific Affairs, LLC, a Johnson & Johnson company.

: M.Z., A.S., A.V., A.T.S., and D.P. are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, a Johnson & Johnson company, which funded the development and conduct of this study. K.J. is an employee of Janssen Scientific Affairs, LLC, a Johnson & Johnson company, and stockholder of Johnson & Johnson. M.K.J. practices in the department of psychiatry at the University of Texas Southwestern Medical Center and has received grants from Acadia, Neurocrine, Navitor/Supernus, and Janssen; consultant fees from Eleusis, Janssen, Worldwide Clinical Trials, Boehringer Ingelheim, and Guidepoint; and honoraria from Psych Congress/NACCME, WebMD, Clinical Care Options, and GME.

: All authors have read and approved the final submitted manuscript. The authors made substantial contributions to the conception or design of the study (all authors), the acquisition, analysis (M.Z., A.S., A.V., A.T.S., and D.P.), and interpretation of data (all authors). Additionally, they contributed to drafting the manuscript (all authors) or revising it critically for important intellectual content (all authors).

: The data that support the findings of this study are available from Merative™ MarketScan® Commercial database and Merative™ MarketScan® Health and Productivity Management (HPM) database. Restrictions apply to the availability of these data, which were used under license for this study.

: All analyses were conducted using SAS Enterprise Guide 9.4 (SAS Institute, Cary, NC). The SAS programs are proprietary materials of Analysis Group, Inc.; therefore, restrictions apply to the access of these codes, which cannot be made available publicly.

: Data were deidentified and complied with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) ().

: Not applicable.

: Not applicable.